rabbit anti dpp4  (Cusabio)

Journal: Frontiers in Oncology

Article Title: CD26 as a potential therapeutic target for lung adenocarcinoma

doi: 10.3389/fonc.2025.1552587

Figure Lengend Snippet: Scoring of CD26 immunohistochemistry. (A–C) Adenocarcinoma scores 1, 2, and 3. (D–F) Squamous cell carcinoma score 1, 2, and no score 3 (F; blank). (G) Adenosquamous score 1. (H, I) Same case of adenosquamous carcinoma with (H) adenocarcinoma component score 2 and (I) squamous cell component score 0. (J–L) Large-cell carcinoma score 1, 2, and no score 3 (blank). Scale bar, 100 µm.

Article Snippet: Antibodies against the following proteins were used: CD26 (1:100 dilution; Cell Signaling, Danvers, MA, US; #67138), Periostin (1:10; Abcam, Cambridge, MA, US; #ab14041), Vimentin (1:250 dilution; Dako, Glostrup, Denmark; M7020), Versican (1:500 dilution; Seikagaku Corporation, Tokyo, Japan; #270428), E-cadherin (1:200 dilution; Cell Marque, Rocklin, CA, US; #246R-16), and β-catenin (1:50 dilution; BD Biosciences, San Jose, CA, US; #610154).

Techniques: Immunohistochemistry

Journal: Frontiers in Oncology

Article Title: CD26 as a potential therapeutic target for lung adenocarcinoma

doi: 10.3389/fonc.2025.1552587

Figure Lengend Snippet: CD26 expression among NSCLC subtypes. Adenocarcinoma expresses significantly more CD26 compared to squamous cell carcinoma (p < 0.0001) and large-cell carcinoma (p = 0.0049). (A) Comparison between adenocarcinoma and adenosquamous carcinoma did not reach statistical significance (p = 0.1104). (B) Comparison of CD26 expression across adenocarcinoma subtypes. Although the overall Kruskal–Wallis test indicated statistical significance (p = 0.0493), none of the pairwise post-hoc comparisons reached significance after correction for multiple testing, suggesting only modest differences among subtypes without robust differences between individual groups. Kruskal–Wallis test, Dunn’s multiple comparisons. **p < 0.01; ****p < 0.0001. NSCLC, non-small cell lung cancer.

Article Snippet: Antibodies against the following proteins were used: CD26 (1:100 dilution; Cell Signaling, Danvers, MA, US; #67138), Periostin (1:10; Abcam, Cambridge, MA, US; #ab14041), Vimentin (1:250 dilution; Dako, Glostrup, Denmark; M7020), Versican (1:500 dilution; Seikagaku Corporation, Tokyo, Japan; #270428), E-cadherin (1:200 dilution; Cell Marque, Rocklin, CA, US; #246R-16), and β-catenin (1:50 dilution; BD Biosciences, San Jose, CA, US; #610154).

Techniques: Expressing, Comparison

Journal: Frontiers in Oncology

Article Title: CD26 as a potential therapeutic target for lung adenocarcinoma

doi: 10.3389/fonc.2025.1552587

Figure Lengend Snippet: Survival function of adenocarcinoma patients estimated by Kaplan–Meier method, stratified by immunohistochemical confirmation of CD26/DPP4 expression (CD26-positive vs. CD26-negative). Time is displayed in months. Patients with CD26/DPP4-expressing tumors show a survival benefit compared to their CD26/DPP4-negative counterparts (n = 463, p = 0.0063, log-rank test).

Article Snippet: Antibodies against the following proteins were used: CD26 (1:100 dilution; Cell Signaling, Danvers, MA, US; #67138), Periostin (1:10; Abcam, Cambridge, MA, US; #ab14041), Vimentin (1:250 dilution; Dako, Glostrup, Denmark; M7020), Versican (1:500 dilution; Seikagaku Corporation, Tokyo, Japan; #270428), E-cadherin (1:200 dilution; Cell Marque, Rocklin, CA, US; #246R-16), and β-catenin (1:50 dilution; BD Biosciences, San Jose, CA, US; #610154).

Techniques: Immunohistochemical staining, Expressing

Journal: Frontiers in Oncology

Article Title: CD26 as a potential therapeutic target for lung adenocarcinoma

doi: 10.3389/fonc.2025.1552587

Figure Lengend Snippet: EMT marker analysis in adenocarcinoma in correlation with CD26/DPP4 expression, Vimentin, Elastin, β-catenin, Periostin, Versican, and E-cadherin (A–F) . Mann–Whitney U-test; **p < 0.01; ****p < 0.0001. (G–I) Serial section analysis of representative cases; each row represents a single case with various staining scores for specific markers. (G) Upper row: Vimentin score 3/CD26/DPP4 score 3. Lower row: Vimentin score 1/CD26/DPP4 negative. (H) Upper row: Elastin score 3, CD26/DPP4 score 2. Lower row: Elastin score 1, CD26/DPP4 negative. (I) Upper row: E-cadherin score 3, CD26/DPP4 score 1. Lower row: E-cadherin score 1, CD26/DPP4 score 3. Scale bar, 100 µm. EMT, epithelial-to-mesenchymal transition.

Article Snippet: Antibodies against the following proteins were used: CD26 (1:100 dilution; Cell Signaling, Danvers, MA, US; #67138), Periostin (1:10; Abcam, Cambridge, MA, US; #ab14041), Vimentin (1:250 dilution; Dako, Glostrup, Denmark; M7020), Versican (1:500 dilution; Seikagaku Corporation, Tokyo, Japan; #270428), E-cadherin (1:200 dilution; Cell Marque, Rocklin, CA, US; #246R-16), and β-catenin (1:50 dilution; BD Biosciences, San Jose, CA, US; #610154).

Techniques: Marker, Expressing, MANN-WHITNEY, Staining

Journal: Frontiers in Oncology

Article Title: CD26 as a potential therapeutic target for lung adenocarcinoma

doi: 10.3389/fonc.2025.1552587

Figure Lengend Snippet: CD26 inhibition by vildagliptin showed reduced colony formation in a dose-dependent manner in the CD26-expressing mouse lung cancer cell line LLC. (A) Mean ± standard deviation, one-way ANOVA, p = 0.0279, False Discovery Rate (FDR) method by Benjamini–Hochberg. In the CD26-positive human lung cancer cell line H460, we observed a similar trend. (B) Mean ± standard deviation, one-way ANOVA, p = 0.0579. LLC, Lewis lung carcinoma.

Article Snippet: Antibodies against the following proteins were used: CD26 (1:100 dilution; Cell Signaling, Danvers, MA, US; #67138), Periostin (1:10; Abcam, Cambridge, MA, US; #ab14041), Vimentin (1:250 dilution; Dako, Glostrup, Denmark; M7020), Versican (1:500 dilution; Seikagaku Corporation, Tokyo, Japan; #270428), E-cadherin (1:200 dilution; Cell Marque, Rocklin, CA, US; #246R-16), and β-catenin (1:50 dilution; BD Biosciences, San Jose, CA, US; #610154).

Techniques: Inhibition, Expressing, Standard Deviation

Journal: Frontiers in Oncology

Article Title: CD26 as a potential therapeutic target for lung adenocarcinoma

doi: 10.3389/fonc.2025.1552587

Figure Lengend Snippet: Pharmacological CD26 inhibition reduced the expression of the EMT marker Vimentin in the lung cancer cell lines LLC and H460, tested in 3D culture conditions (A, B) . N-cadherin remained unchanged by vildagliptin treatment (C, D) . Student’s t-test: *p < 0.05. EMT, epithelial-to-mesenchymal transition; LLC, Lewis lung carcinoma.

Article Snippet: Antibodies against the following proteins were used: CD26 (1:100 dilution; Cell Signaling, Danvers, MA, US; #67138), Periostin (1:10; Abcam, Cambridge, MA, US; #ab14041), Vimentin (1:250 dilution; Dako, Glostrup, Denmark; M7020), Versican (1:500 dilution; Seikagaku Corporation, Tokyo, Japan; #270428), E-cadherin (1:200 dilution; Cell Marque, Rocklin, CA, US; #246R-16), and β-catenin (1:50 dilution; BD Biosciences, San Jose, CA, US; #610154).

Techniques: Inhibition, Expressing, Marker